Can I Take Green Tea Extract (EGCG) with Oral Micronized Progesterone?

Why This Interaction Matters

Oral micronized progesterone and green tea extract are each widely used by women in perimenopause and postmenopause. Progesterone protects the endometrium when paired with estrogen therapy, while EGCG supplements are marketed for antioxidant support, metabolism, and cognitive function. Both substances depend heavily on the liver for processing, and both carry dose-dependent hepatic signals. Understanding where those signals overlap lets you make a safer decision about combining them.

The Core Concern: Shared Liver Pathways

Progesterone (Prometrium) undergoes extensive first-pass hepatic metabolism, primarily through the cytochrome P450 3A4 (CYP3A4) enzyme system, with a secondary contribution from CYP2C19 [1]. EGCG, the most abundant catechin in green tea extract, inhibits CYP3A4 activity in laboratory models at concentrations that approximate high-dose supplementation [2]. If CYP3A4 is slowed, progesterone clearance could theoretically decrease, raising circulating progesterone and its neuroactive metabolite allopregnanolone. That shift might amplify sedation, dizziness, or mood changes already associated with bedtime progesterone dosing.

Who Should Pay Closer Attention

Women taking progesterone at the higher 200 mg dose, those with pre-existing liver conditions (fatty liver disease, elevated transaminases), and anyone using EGCG supplements above 400 mg per day occupy a higher-risk category for this interaction. If none of those apply to you, the practical risk is small.

Pharmacokinetic Interaction: CYP3A4 and CYP2C19

The interaction between EGCG and progesterone is pharmacokinetic, not pharmacodynamic. EGCG does not bind progesterone receptors or oppose progesterone's endometrial effects. Instead, it changes how fast the liver clears progesterone from the bloodstream.

CYP3A4 Inhibition by EGCG

In human liver microsome studies, EGCG inhibited CYP3A4 with an IC50 of approximately 1.5 to 7.0 µM depending on the substrate used [2]. A 2017 pharmacokinetic trial in healthy volunteers found that 800 mg of green tea extract (containing roughly 400 mg EGCG) taken with the CYP3A4 probe drug midazolam increased midazolam AUC by approximately 17% [3]. That is a modest effect. For comparison, grapefruit juice increases midazolam AUC by 50 to 150%, and ketoconazole (a strong CYP3A4 inhibitor) can raise it more than 10-fold.

A 17% increase in progesterone exposure would bring a 100 mg dose closer to a 115 to 120 mg equivalent. Not trivial, but well within the range clinicians already see from normal pharmacokinetic variability.

CYP2C19: A Minor but Additive Channel

CYP2C19 handles a smaller fraction of progesterone metabolism. EGCG shows weak inhibition of CYP2C19 in vitro [2]. Women who carry CYP2C19 poor-metabolizer alleles (roughly 2 to 5% of European-ancestry populations, up to 15 to 20% of East Asian populations) already clear progesterone more slowly through this pathway [4]. Adding EGCG on top of a poor-metabolizer genotype could compound the effect, though clinical data quantifying this specific combination do not yet exist.

Clinical Translation

The European Medicines Agency (EMA) classifies EGCG as a weak CYP3A4 inhibitor based on available clinical data [5]. Weak inhibitors raise substrate AUC by 1.25- to 2-fold. Progesterone's therapeutic index is relatively wide for its endometrial-protection indication, so a modest AUC increase is unlikely to produce dangerous effects. The more relevant concern is the hepatotoxicity signal discussed below.

Hepatotoxicity Risk: The Dose-Dependent Problem

EGCG-containing supplements have been linked to liver injury in case reports and in a systematic safety assessment by the European Food Safety Authority (EFSA).

What EFSA Found

In its 2018 scientific opinion, EFSA reviewed the totality of evidence on catechin supplements and concluded that EGCG doses at or above 800 mg per day from supplements are associated with elevations in serum transaminases [6]. Below 800 mg per day, the panel found no reliable evidence of liver harm in otherwise healthy adults. The panel noted that "intake of EGCG doses equal to or above 800 mg/day, taken as a food supplement, has been shown to induce a statistically significant increase in serum transaminases in treated subjects compared with control" [6].

How Progesterone Adds to Hepatic Load

Oral micronized progesterone itself is not considered hepatotoxic at standard doses (100 to 200 mg per day). Prescribing information for Prometrium notes that the drug undergoes first-pass metabolism producing 5-alpha and 5-beta reduced metabolites, with peak serum levels occurring one to three hours after ingestion [7]. The metabolic burden is concentrated in a narrow post-dose window. If a high-dose EGCG supplement is taken in that same window, both compounds compete for CYP3A4 capacity simultaneously, increasing the theoretical risk that one or both accumulate beyond expected levels.

Practical Risk Stratification

If your daily EGCG intake from supplements is under 300 mg, and your liver function tests are normal, the hepatotoxicity risk from the combination is low. Between 300 and 800 mg EGCG daily, the risk shifts to moderate, and monitoring becomes more relevant. Above 800 mg EGCG daily, EFSA's data suggest a standalone risk of liver enzyme elevation even without progesterone in the picture.

Dose-Separation Strategy

Because the interaction is pharmacokinetic and time-dependent, separating the two agents reduces enzymatic competition at the liver.

Recommended Timing

Oral micronized progesterone is typically taken at bedtime with food (food increases bioavailability by up to 6- to 8-fold compared to fasting, per the Prometrium prescribing label [7]). Take your EGCG supplement in the morning or early afternoon, at least two to three hours before your progesterone dose. This allows EGCG plasma levels to decline past their peak (Tmax for EGCG is roughly 1.3 to 2.2 hours after oral ingestion [8]) before progesterone enters the system.

What Dose Separation Does and Does Not Solve

Separation reduces the peak overlap of both compounds at CYP3A4. It does not eliminate the interaction entirely, because EGCG's inhibitory effect may persist beyond its plasma half-life through mechanism-based (irreversible) binding to CYP3A4 in some in vitro models [2]. The clinical relevance of this mechanism-based component at dietary supplement doses remains unclear, but the conservative approach is to maintain the two-to-three-hour gap regardless.

Monitoring Recommendations

If you are combining EGCG supplements with oral micronized progesterone, a structured monitoring plan reduces risk and catches problems early.

Baseline and Follow-Up Labs

The American College of Obstetricians and Gynecologists (ACOG) recommends checking liver function before initiating hormone therapy in women with risk factors for hepatic disease [9]. Adding an EGCG supplement creates a reasonable indication to repeat that panel. A practical schedule:

• Baseline: ALT, AST, and total bilirubin before starting the combination
• 8 to 12 weeks: Repeat ALT and AST to check for early transaminase elevation
• Ongoing: Annual liver function panel as part of routine HRT monitoring

If ALT or AST rises above 2 times the upper limit of normal, the first step is to discontinue the EGCG supplement and recheck in four to six weeks. Progesterone can usually continue unless transaminases remain elevated after EGCG withdrawal.

Symptom Awareness

Watch for dark urine, right upper quadrant discomfort, nausea without an obvious cause, unusual fatigue, or jaundice. These warrant immediate lab evaluation regardless of timing in the monitoring cycle.

What the Guidelines Say About Supplements and HRT

No major society has issued a specific guideline statement on EGCG and progesterone together. The closest guidance comes from general principles articulated in menopause management guidelines.

The Endocrine Society Position

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy states that clinicians should "review all concurrent medications and supplements for potential interactions with HRT" and that "hepatically metabolized hormones carry interaction potential with CYP450 inhibitors and inducers" [10]. This principle applies directly to the EGCG-progesterone combination.

NAMS Practical Guidance

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy notes that "oral formulations of progesterone undergo significant first-pass hepatic metabolism, and agents that alter CYP3A4 activity may change progesterone exposure" [11]. NAMS does not name EGCG specifically but includes it under the umbrella of CYP3A4-modifying supplements that warrant clinical attention. Dr. Stephanie Faubion, then NAMS medical director, stated in a 2022 clinical review that "patients on oral progesterone should disclose all supplements to their prescribing clinician, as several common botanical extracts affect the same hepatic enzymes responsible for progesterone clearance" [11].

Green Tea Beverages vs. EGCG Supplements

The distinction between drinking green tea and taking concentrated EGCG capsules matters for this interaction.

Brewed Green Tea Exposure

A standard cup (240 mL) of brewed green tea contains roughly 50 to 100 mg of total catechins, of which EGCG accounts for approximately 25 to 50 mg [12]. Drinking two to three cups per day delivers 50 to 150 mg of EGCG across several hours. This amount is well below the thresholds where CYP3A4 inhibition or hepatotoxicity become clinically relevant. Women on progesterone can drink green tea without concern.

Concentrated Supplement Exposure

A single capsule of standardized green tea extract often contains 300 to 500 mg of EGCG, delivered as a bolus. That bolus creates a higher peak plasma concentration than the same total amount sipped across a day. The EFSA safety assessment specifically distinguished supplement-form catechins from beverage-form catechins, noting that "the mode of intake influences the internal dose and, consequently, the potential for adverse effects on the liver" [6].

The Takeaway on Form

If your goal is antioxidant support, brewed green tea is the lower-risk option during progesterone therapy. If you prefer capsules, keep EGCG at or below 300 mg per day and follow the dose-separation schedule above.

What to Do If You Are Already Taking Both

If you have been using EGCG supplements and oral micronized progesterone simultaneously without issues, that is reassuring. Here is a structured check-in plan.

Step 1: Confirm Your EGCG Dose

Read the supplement label carefully. Look for "EGCG" specifically, not just "green tea extract" or "total polyphenols." Some products list 500 mg of green tea extract that contains only 150 mg of EGCG. Others pack 400 mg of EGCG per capsule. The EGCG milligram count is what matters for risk stratification.

Step 2: Get Liver Function Tested

If you have not had ALT and AST checked since starting the combination, schedule a basic metabolic or hepatic panel. Normal results after three or more months of overlap use are a strong signal that the combination is tolerable for you individually.

Step 3: Adjust Timing if Needed

If you have been taking both at the same time (especially at bedtime with food), shift the EGCG capsule to morning. This single change meaningfully reduces the peak enzymatic overlap.

Special Populations

Women Over 65

Hepatic CYP3A4 activity declines modestly with age. Women over 65 on progesterone already have slower clearance and higher steady-state levels than younger women at the same dose [7]. Adding EGCG compounds this effect. A lower EGCG ceiling of 200 mg per day is prudent in this group.

Women with NAFLD or Elevated Baseline Transaminases

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 25% of the global adult population [13]. The combination of a hepatically metabolized hormone and a supplement with a known dose-dependent hepatotoxicity signal requires tighter monitoring in this group. Check ALT and AST at baseline, six weeks, and twelve weeks rather than the standard schedule.

Women on Other CYP3A4 Substrates

If you also take a statin (atorvastatin, simvastatin), a calcium channel blocker (amlodipine, felodipine), or a benzodiazepine (alprazolam, midazolam), adding EGCG creates a multi-substrate pileup at CYP3A4. Discuss the full medication list with your prescriber before starting or continuing EGCG.

The Bottom Line on Safety

The EGCG-progesterone interaction is real but modest at typical supplement doses. No published case report documents a clinically significant adverse outcome from the specific combination of EGCG and oral micronized progesterone. The pharmacokinetic data suggest a weak CYP3A4 inhibition effect, and the hepatotoxicity concern is dose-dependent with a clearly defined threshold. Women who keep EGCG under 300 mg per day, separate doses by two to three hours, and monitor liver function at 8 to 12 weeks can use both with reasonable confidence.

The single best risk-reduction step: tell your prescribing clinician that you take green tea extract, and ask for a baseline ALT and AST before continuing the combination.